33130-04-0

Basic information

• Product Name: 3-(2,3,4-TRIMETHOXYPHENYL)PROPIONIC ACID
• Synonyms: 3-(2,3,4-TRIMETHOXYPHENYL)PROPIONIC ACID;BETA-(2,3,4-TRIMETHOXYPHENYL)PROPIONIC ACID;B-(2,3,4-TRIMETHOXYPHENYL)PROPIONIC ACID;3-(2,3,4-TRIMETHOXYPHENYL)PROPIONIC ACID, 98+%
• CAS NO: 33130-04-0
• Molecular Formula: C₁₂H₁₆O₅
• Molecular Weight: 240.25
• EINECS: 251-389-0
• Product Categories: Aromatic Propionic Acids
• Mol File: 33130-04-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 70-73℃
• Boiling Point: 362.3 °C at 760 mmHg
• Flash Point: 134.8 °C
• Appearance: /
• Density: 1.169 g/cm³
• Vapor Pressure: 6.99E-06mmHg at 25°C
• Refractive Index: 1.515
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-(2,3,4-TRIMETHOXYPHENYL)PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2,3,4-TRIMETHOXYPHENYL)PROPIONIC ACID(33130-04-0)
• EPA Substance Registry System: 3-(2,3,4-TRIMETHOXYPHENYL)PROPIONIC ACID(33130-04-0)

Safety Data

• Hazardous Substances Data: 33130-04-0(Hazardous Substances Data)

Usage

General Description

3-(2,3,4-Trimethoxyphenyl)propionic acid is a chemical compound that belongs to the class of phenylpropanoids. It is a white solid with a molecular formula of C12H16O5 and a molecular weight of 240.25 g/mol. This chemical compound is often used as an intermediate in the synthesis of various pharmaceuticals and biologically active compounds. It has anti-inflammatory and analgesic properties, which make it a potential candidate for the development of new drugs for treating pain and inflammation-related conditions. Additionally, 3-(2,3,4-Trimethoxyphenyl)propionic acid has been studied for its antioxidant and neuroprotective effects, showing potential therapeutic applications in the field of neurology.

InChI:InChI=1/C12H16O5/c1-15-9-6-4-8(5-7-10(13)14)11(16-2)12(9)17-3/h4,6H,5,7H2,1-3H3,(H,13,14)

Upstream product

• 141-78-6 ethyl acetate 
• 2103-57-3 2,3,4-trimethoxybenzaldehyde 
• 33130-03-9 3-(2,3,4-trimethoxyphenyl)acrylic acid 
• 634-36-6 1,2,3-trimethoxybenzene 
• 116406-19-0 trans-2,3,4-trimethoxycinnamic acid 

Downstream Products

• 934176-50-8 (5-{2-[3-(2,3,4-trimethoxy-phenyl)-propionylamino]-phenyl}-thiophen-2-yl)-acetic acid methyl ester 
• 4228-71-1 6-Hydroxydopamin 
• 3937-16-4 2-(2,3,4-trimethoxyphenyl)ethylamine 
• 864518-28-5 {3-[3-(2,3,4-Trimethoxy-phenyl)-propionylamino]-phenyl}-acetic acid methyl ester 
• 1057673-90-1 3-(2,3,4-trimethoxy-phenyl)-propionic acid ethyl ester 

Relevant articles and documents

TUBULIN BINDING AGENTS

The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity). The compounds are based on the combretastatin A-4 skeletal structure having a tubulin-binding pharmacophore comprising two fused rings (A and B rings) in which the B ring is substituted with (a) an aromatic ring structure (C ring) and (b) a second substituent/functional group that comes off the B ring. The aromatic ring structure is typically a six membered ring phenolic or aniline structure, or may also be a fused ring structure such as a substituted or unsubstituted naphthalene. The second substituent on the B ring may for example be a substituent which has been found to provide enhanced tubulin binding activity (for example a carbonyl group), or may be a substituent that facilitates functionalisation of the B ring (for example an hydroxyl or amine group), or it may be a binding agent for a target that is preferentially expressed on vasculature undergoing angiogenesis, and not expressed on quiescent vasculature.

Synthesis, biological evaluation and mechanism study of a class of benzylideneindanone derivatives as novel anticancer agents

A series of new benzylideneindanone derivatives were designed, synthesized and evaluated as antitumor agents. Structure-activity relationship (SAR) studies showed that derivatives with 4,5,6-trimethoxyl on an indanone moiety displayed good anti-proliferative activities. Especially, compound 5a demonstrated the most potent inhibitory activity, with GI50 values from 0.172 to 0.57 μM for five kinds of cancer cell lines. Further investigation showed that 5a could inhibit microtubule polymerization and thus induce G2/M phase arrest and apoptosis in A549 cells. Our findings revealed the benzylideneindanone moiety as a new attractive scaffold for mitosis-targeting drug discovery.

Method of inhibiting sweetness

The sweetness of an ingestible product containing a sweetening sugar or sugar alcohol in large quantities can be reduced by incorporating therein a sweetness-reducing amount of at least one compound of the general formula: STR1 in which m represents 0 or 1, and when m represents 0, n represents 1, 2 or 3, and p represents 1, 2, 3 or 4, and when m represents 1, n represents 1 or 2 and p represents 0, 1, 2, 3 or 4; the substituents R, which may be the same or different, each represent a lower alkoxy group, e.g. with 1 to 5 carbon atoms, phenoxy group or a lower alkyl or trifluoromethyl group; and/or two substituents R together represent an aliphatic chain linked to the phenyl ring at two positions, either directly or via an oxa-group, e.g. an alkylenedioxy, alkenylenedioxy, alkylenoxy or alkenylenoxy group; and/or one substituent R represents a hydroxy group while at least one other substituent R represents an alkoxy group; and X+ represents a physiologically acceptable cation.